SEC Tracker
Get the app

CRISPR Therapeutics CRSP

CRISPR Therapeutics reports Q3 2026 results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. CASGEVY revenue of $99 million in Q3 2026, up 30% quarter-over-quarter
  2. FDA granted RMAT designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C
  3. CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when CRISPR Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

0 of 2 claims matched the filing text.

Not found in the filing text

  • For the quarter ended June 30, 2026, CRISPR Therapeutics AG reported revenue of $10.2 million and a net loss of $91.2 million.
  • The company's operating margin was -1151.8% and its net margin was -895.3% for the same period.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025
  2. Adma Biologics ADMA public float $4.2B, Jun 30, 2025
  3. Lantheus Holdings LNTH public float $4.3B, Jun 30, 2025
  4. Merus MRUS
  5. Axsome Therapeutics AXSM public float $4.4B, Jun 30, 2025